Serum Immunoglobulin A Anti-Endomysial Antibody (IgA-EMA) and its Effectiveness in Screening for Celiac Disease in the Pediatric Population with Diabetes Mellitus 1 by McCauley, Lily
Pacific University
CommonKnowledge
School of Physician Assistant Studies Theses, Dissertations and Capstone Projects
8-15-2009
Serum Immunoglobulin A Anti-Endomysial
Antibody (IgA-EMA) and its Effectiveness in
Screening for Celiac Disease in the Pediatric
Population with Diabetes Mellitus 1
Lily McCauley
Pacific University
Follow this and additional works at: http://commons.pacificu.edu/pa
Part of the Medicine and Health Sciences Commons
This Capstone Project is brought to you for free and open access by the Theses, Dissertations and Capstone Projects at CommonKnowledge. It has
been accepted for inclusion in School of Physician Assistant Studies by an authorized administrator of CommonKnowledge. For more information,
please contact CommonKnowledge@pacificu.edu.
Recommended Citation
McCauley, Lily, "Serum Immunoglobulin A Anti-Endomysial Antibody (IgA-EMA) and its Effectiveness in Screening for Celiac
Disease in the Pediatric Population with Diabetes Mellitus 1" (2009). School of Physician Assistant Studies. Paper 158.
Serum Immunoglobulin A Anti-Endomysial Antibody (IgA-EMA) and its
Effectiveness in Screening for Celiac Disease in the Pediatric Population
with Diabetes Mellitus 1
Abstract
INTRODUCTION: Diabetes Mellitus Type 1 (DM 1) and celiac disease (CD) are both autoimmune
diseases that are associated with the human leukocyte antigen (HLA)-DQ2 and human leukocyte antigen
(HLA)-DQ8 genetic halotypes. Different geographical areas vary with prevalence of CD in populations with
DM 1, ranging from 1.1% to 16.4%. Type 1 diabetes is a chronic autoimmune disease and accounts for
approximately two thirds of all new diagnoses of diabetes in patients 19 years of age and younger, with a
continue rise in incidence. Celiac disease is also an autoimmune disorder, and is characterized by intestinal
villous damage caused by gluten ingestion. In the United States and Western Europe, the prevalence is
approximately 1%. Individuals are susceptible to celiac disease on average, within 10 years of their DM 1
diagnosis. The incidence of celiac disease is increasing in those with type 1 diabetes because screening for CD
has been made possible with the availability of non-invasive serological testing. Immunoglobulin A anti-
endomysial antibody (IgA- EMA) has high sensitivity and specificity for celiac disease and has been proven to
be effective in diagnosing atypical and latent CD. However, the “gold” standard for celiac diagnosis is the
intestinal biopsy.
METHODS: The focus of this study was to review the current literature on all studies pertaining to IgA-EMA
screening for celiac disease in the pediatric population with type 1 diabetes. The studies involved screening of
type 1 diabetic patients for celiac disease with IgA- EMA and intestinal biopsies for those who tested positive
for IgA- EMA.
RESULTS: The seven studies showed high prevalence of celiac disease in pediatric individuals with type 1
diabetes. Several studies also demonstrated that those who were initially negative for celiac disease later
developed latent celiac disease.
CONCLUSION: IgA-EMA is an effective screening test for celiac disease in individuals with type 1 diabetes.
The studies reported that due to the high prevalence of celiac disease in conjunction with type 1 diabetes,
initial screening for celiac disease at diabetes onset is recommended and should be performed. They also
stated that since seroconversion could occur, and patients could develop latent celiac disease, screening for
celiac disease should also be performed after diabetes onset. How often and at what interval screening should
be done is unanswered.
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Abstract   
INTRODUCTION:  Diabetes Mellitus Type 1 (DM 1) and celiac disease (CD) are both autoimmune 
diseases that are associated with the human leukocyte antigen (HLA)-DQ2 and human leukocyte 
antigen (HLA)-DQ8 genetic halotypes. Different geographical areas vary with prevalence of CD in 
populations with DM 1, ranging from 1.1% to 16.4%. Type 1 diabetes is a chronic autoimmune disease 
and accounts for approximately two thirds of all new diagnoses of diabetes in patients 19 years of age 
and younger, with a continue rise in incidence. Celiac disease is also an autoimmune disorder, and is 
characterized by intestinal villous damage caused by gluten ingestion. In the United States and 
Western Europe, the prevalence is approximately 1%. Individuals are susceptible to celiac disease on 
average, within 10 years of their DM 1 diagnosis. The incidence of celiac disease is increasing in those 
with type 1 diabetes because screening for CD has been made possible with the availability of non-
invasive serological testing. Immunoglobulin A anti-endomysial antibody (IgA- EMA) has high 
sensitivity and specificity for celiac disease and has been proven to be effective in diagnosing atypical 
and latent CD.  However, the “gold” standard for celiac diagnosis is the intestinal biopsy. 
METHODS: The focus of this study was to review the current literature on all studies pertaining to 
IgA-EMA screening for celiac disease in the pediatric population with type 1 diabetes. The studies 
involved screening of type 1 diabetic patients for celiac disease with IgA- EMA and intestinal biopsies 
for those who tested positive for IgA- EMA. RESULTS: The seven studies showed high prevalence of 
celiac disease in pediatric individuals with type 1 diabetes.  Several studies also demonstrated that 
those who were initially negative for celiac disease later developed latent celiac disease.  
CONCLUSION: IgA-EMA is an effective screening test for celiac disease in individuals with type 1 
diabetes. The studies reported that due to the high prevalence of celiac disease in conjunction with type 
1 diabetes, initial screening for celiac disease at diabetes onset is recommended and should be 
performed. They also stated that since seroconversion could occur, and patients could develop latent 
celiac disease, screening for celiac disease should also be performed after diabetes onset. How often 
and at what interval screening should be done is unanswered. KEYWORDS: celiac disease, diabetes 
mellitus type 1, pediatric, children, adolescents, anti-endomysial antibody (EMA) and immunoglobulin 
A anti-endomysial antibody (IgA-EMA).  
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Serum Immunoglobulin A Anti-Endomysial Antibody (IgA-EMA) and its Effectiveness in Screening 
for Celiac Disease in the Pediatric Population with Diabetes Mellitus 1 
 
Introduction 
Celiac Disease 
 Celiac disease (CD) is an autoimmune disease that is characterized by intestinal villous damage 
due to gluten ingestion.  Gluten is found in wheat, barley, rye and possibly in oats. The ingestion of 
gluten involves T cells, lymphocytes and cytokines. The small intestinal epithelium is damaged by the 
cytokines, which trigger the release of the enzyme tissue transglutaminase (tTG), which then causes an 
increase in cytokine production. Inflammation, destruction of the intestinal villi, and crypt hypertrophy 
are caused by increased epithelial damage; an increase in plasma cells, macrophages, and lymphocytes; 
and the migration of lymphocytes to the surface of the epithelium. This cascade of inflammatory 
processes causes a lack of absorptive surface area and a decrease in the uptake of nutrients. However, 
the damage to the intestine can resolve itself when the gluten is removed.1 
  In most pediatric cases celiac disease presents during the second year of life although the age of 
onset and severity are variable. The most common symptoms in the pediatric population are diarrhea, 
constipation, vomiting, abdominal pain, failure to thrive, anemia, and vitamin deficiencies. 2 There are 
four categories of celiac disease: 1) classic celiac disease includes the symptoms mentioned previously, 
the presence of characteristic histological changes on small intestinal biopsy, and the resolution of 
mucosal lesions and symptoms upon withdrawal of gluten containing foods. 2) Atypical celiac disease 
involves pre-dominant extra-intestinal manifestations with few gastrointestinal symptoms. The 
diagnosis is similar in those with the classic disease and requires serological testing, biopsy of villous 
atrophy and symptom improvement on a gluten free diet. 3) In the case of silent/subclinical celiac 
disease these patients have a positive specific serologic test for celiac disease and biopsy evidence of 
villous atrophy, but no discernable symptoms. This condition is usually detected by screening of high 
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risk groups. After treatment with a gluten free diet many of these patients in retrospect recognize 
having had symptoms that they previously thought were normal. 3 
 In the United States and Western Europe, the estimated prevalence of celiac disease is 
approximately 1%. The incidence continues to rise, which may be due to increased awareness and 
screening. According to the Celiac Disease Foundation, CD occurs in 5%-15% of the offspring and 
siblings of a person with celiac disease and in 70% of identical twin pairs. There is a 25% increased 
risk for developing celiac disease in family members who have any autoimmune disease. 1 
 
Type I Diabetes 
 Type 1 diabetes (DM 1) is a chronic autoimmune disease, previously called juvenile diabetes or 
insulin-dependent mellitus (IDDM). Type 1 diabetes is the most common type of diabetes in 
individuals younger than 40 years of age. Insulin is produced in the beta cells of the pancreatic islets 
and type 1 diabetes results from immunological damage to these insulin producing cells. In most 
people, this damage is gradual, occurring over months or even years. Symptoms of diabetes do not 
appear until approximately 90% of the pancreatic islets have been destroyed. 4 
 Type 1 diabetes accounts for approximately two thirds of new diagnoses of diabetes in patients 
19 years of age and younger in the United States.   Worldwide, the incidence of type 1 diabetes varies, 
ranging from 0.1 to 37 per 100,000 children younger than 15 years of age. The reported incidence is 15 
to 17 per 100,000 children in the United States.  “The age of presentation has a bimodal distribution 
with peaks at 4 to 6 years of age and again between 10 and 14 years of age.” 5 
  The risk of DM I increases significantly in close relatives of a patient of with type 1 diabetes. 5 
After the first twin develops diabetes 35%-50% of second identical twins develop diabetes.  
Approximately 6% of offspring or siblings with type I diabetes also develop type 1 diabetes.4   
Exposure to one or more environmental agents seems to trigger an immune response in genetically 
9 
 
susceptible individuals that causes destruction of the pancreatic beta cells. According to several 
reports, these  environmental factors such as viral infections, immunizations, diet (exposure to cow’s 
milk at an early age), vitamin D deficiency, perinatal factors  (maternal age, history of preeclampsia, 
and neonatal jaundice), and low birth weight,  increase the risk of type 1 diabetes. However, none of 
these associations have been confirmed and there are studies that are contradictory.  5  
 The most common presentation of type 1 diabetes in childhood is hyperglycemia without 
acidosis. Hyperglycemia causes the following symptoms: polyuria, polydipsia, weight loss despite 
increased appetite, and lethargy.  Children with type 1 diabetes that present with ketoacidosis (DKA) 
have similar but more severe symptoms than those without acidosis. 5 For the diagnosis of DKA, 
hyperglycemia (blood glucose greater than 200 mg/dl) and metabolic acidosis, which is defined as a 
venous pH <7.3 and/or plasma bicarbonate less than 15 meq/L, must be present. Diabetic ketoacidosis 
is often the initial diagnosis of children with new onset type 1 diabetes and risk factors include: higher 
A1C levels and higher reported insulin requirements, female adolescents (with the highest risk in 
females over the age of 13 years old), children who are 13 years old, regardless of gender, who are 
underinsured and/or have a history of psychiatric disorders, and longer duration of diabetes.  The 
earliest symptoms of DKA are similar to those in hyperglycemia. However, more severe symptoms 
include fatigue, weight loss, nocturia , daytime enuresis, and vaginal or cutaneous moniliasis 
(candidiasis of skin, manifested as eczema). If urinary losses are not replaced then hypovolemia may 
be severe.  Hospitalization, rehydration, and insulin replacement therapy is important for children with 
DKA. Before the onset of clinical symptoms, some children will be diagnosed with type 1 diabetes. 
This occurs in children who have another close family member with DM 1 diabetes and who are being 
closely monitored. This is a silent presentation of DM and is the least common. The diagnosis of DM 1 
is made when a clinician has a high index of suspicion. Although there is no current recommendation 
for pancreatic autoantibody screening, children with an affected close family member may undergo 
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this screening. The diagnosis of DM 1 cannot be made with autoantibody elevation alone; there must 
also be an elevated blood glucose concentration. 5 
 Diabetes is diagnosed based upon one of the three detected abnormalities of glucose 
metabolism, a fasting plasma glucose greater than or equal to126 mg/dL on at least two occasions,  
symptoms of hyperglycemia and a plasma glucose greater than or equal to 200 mg/dL, and an 
abnormal oral glucose tolerance test with a two hour blood glucose greater than 200 mg/dL. 5 
 
Type I Diabetes and Celiac Disease 
 Through screening programs in children with type 1 diabetes, there is an increased prevalence 
of celiac disease compared with non-diabetic children. Different geographical areas vary in the 
prevalence of CD in populations with DMI, ranging from 1.1% to 16.4%. 6 Both celiac disease and 
diabetes share an increased incidence of certain histocompatibility antigens such as human leukocyte 
antigen (HLA)-DQ2 and human leukocyte antigen (HLA) - DQ8, which seems to support the idea that 
both of these autoimmune diseases have a genetic pre-disposition.  On average, within 10 years of their 
diabetic diagnosis, those who are susceptible will develop celiac disease. However, research has shown 
that late seroconversion occurs resulting in an underestimation of the prevalence of CD in type 1 
diabetics.1 
 Screening for celiac disease has been made possible by the availability of sensitive non-
invasive serological testing. The immunoglobulin A anti-endomysial antibody (IgA-EMA) 
measurements, have high diagnostic specificity and sensitivity. This test has been proven to be 
effective in screening both atypical and latent forms of celiac disease. IgA deficiency occurs, however, 
in approximately 3% of the diabetic and celiac disease population and should be tested for because IgA 
deficiency can give false negative IgA-EMA results, which can cause a potential celiac disease 
diagnosis to be missed. Most DM 1 patients with celiac disease do not present with typical 
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gastrointestinal symptoms even in the presence of intestinal lesions.6 More common initial findings of 
CD in patients with DM 1 include unpredictable blood glucose measurements, recurrent episodes of 
hypoglycemia, reduced bone mineralization, and poor glycemic control and growth failure because of 
erratic intestinal absorption of nutrients. 7 With intestinal biopsies, a wide range of histopathological 
abnormalities such as an increased number of intraepithelial lymphocytes to a completely atrophic 
mucosa can be found in the intestinal mucosa of diabetic children. Performing IgA-EMA screening in 
diabetic patients allows, for early identification, treatment of celiac disease, and the prevention of 
symptoms and a reduction in long- term morbidity.6The patient should be referred to a 
gastroenterologist for confirmatory small bowel biopsy if the IgA-EMA test is positive. If the biopsy is 
positive for celiac disease then the patient should be placed on a gluten free diet.  A registered dietitian, 
who has experience in caring for patients with both diabetes and celiac disease should provide, 
nutritional counseling because gluten free dietary substitutes are often high in carbohydrates. 
Identifying gluten free products with an acceptable amount of carbohydrates is important for 
management of patients with both diabetes and celiac disease. 7 
 Due to the prevalence of celiac disease and its impact on type 1 diabetes, it is recommended 
that all children with DM 1 diabetes be screened for celiac disease. If IgA-EMA is negative, then 
patients should be rescreened. If the child develops symptoms suggestive of celiac disease, or 
demonstrates poor growth or weight loss, screening should be performed earlier. 7 Although there are 
several blood tests used in the screening of celiac disease, this paper focuses on the immunoglobulin 
anti-endomysial antibody (IgA-EMA) due to its high specificity and sensitivity. This paper will also 
focus and address the question of how often it is necessary to screen for celiac disease after the onset 
of diabetes mellitus 1 and if screening is necessary if initial IgA-EMA test is negative.  
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Materials and Methods 
 A comprehensive literature search was compiled using the keywords: diabetes mellitus 1, celiac 
disease, adolescents, children, pediatric, anti-endomysial antibody (EMA) and immunoglobulin A anti-
endomysial antibody (IgA-EMA) on Ovid-Medline, CINAHL, MD Consult, Evidence Based Medicine 
Reviews Multifile, UpToDate Inc., and Current Diagnosis and Treatment in Pediatrics. Literature from 
1998 to present was reviewed and weighted towards importance in answering the clinical question. 
The results were then compiled and analyzed.  The inclusion criteria were all relevant English 
language articles that aided in explaining the importance of immunoglobulin A- anti-endomysial 
antibody, screening for celiac disease in the pediatric population with type 1 diabetes. Exclusion 
criteria included articles that discussed other autoimmune disorders, discussion of the adult population, 
and studies that offered other screening tests besides IgA-EMA.  
Results  
 A total of seven English language studies were published between 1998 and 2008, addressing 
the increased prevalence of celiac disease in the pediatric population with type 1 diabetes. All of these 
studies utilized in this systematic reviewed performed immunoglobulin A anti-endomysial antibody 
(IgA-EMA) screening in the diabetic pediatric population and if the IgA-EMA was positive, intestinal 
biopsies were performed. Each article was reviewed and graded on the following criteria:  sample size, 
whether or not biopsy results were affected based on IgA- EMA results, and methods/ criteria used to 
diagnosis celiac disease.  
 Between October 1995 and April 1997, Fraser-Reynolds et al. performed a prospective cohort 
study to determine if the serological marker, the immunoglobulin A anti-endomysial antibody (IgA-
EMA) could be used to screen for celiac disease in North American children with type 1 diabetes. The 
subjects included 236 diabetes clinical patients (two additional diabetic patients were diagnosed with 
celiac disease before this study and were not included) and 56 gastrointestinal clinic patients, who 
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underwent intestinal biopsy for suspected malabsorption. Total IgA and IgA-EMA assays were 
performed. Diabetics were asked to undergo biopsies if they were positive for IgA-EMA.  An 
experienced histopathologist, who was blinded to patient data, assessed the tissue sections for celiac 
disease using the following abnormalities, villous atrophy crypt hyperplasia, an increased in 
intraepithelial lymphocytes (IEL) and chronic inflammation in the lamina propria. Celiac disease was 
defined as an increased number of intraepithelial lymphocytes with associated subtotal villous atrophy 
or total villous atrophy. None of the diabetic patients were IgA deficient and 19 of the 236 diabetic 
patients were positive for IgA-EMA (8%). 17 patients were biopsied (2 refused), 12 had celiac disease 
and 3 out of the 12 patients were symptomatic (1 had loose stools and 2 had frequent stools and 
bloating). The estimated prevalence of celiac disease for diabetic patients in this study was 5.1% (12 
/236). Three of the 56 gastrointestinal patients were IgA-EMA positive and had biopsies diagnostic of 
celiac disease. Another three individuals were found to be IgA deficient and one out of the three IgA 
deficient patients had celiac disease. Of the 50 IgA sufficient and IgA-EMA negative patients, one had 
celiac disease and 49 did not.  The estimated prevalence of celiac disease for the gastrointestinal 
patients was 8.9% (5/56). Sensitivity was calculated by dividing the number of patients with a jejunal 
biopsy indicative of celiac disease, who were IgA-EMA positive, by the total number of patients with a 
jejunal biopsy indicative of celiac disease multiplied by 100. Specificity was calculated by dividing the 
number of patients with a normal jejunal biopsy and a negative IgA-EMA test by the total number of 
all the patients with a normal jejunal biopsy, multiplied by 100. The IgA-EMA test in this study had a 
sensitivity of 94% and a specificity of 91%.One of the 17 IgA-EMA positive diabetic patients 
underwent multiple biopsies. The first biopsy was normal. However, 6 months later a second biopsy 
was performed because of erratic blood glucose control and persistent post-prandial abdominal 
discomfort. The second biopsy showed total villous atrophy. This increased the initial prevalence of 
5.1% to 5.5%. There was no difference in the mean age of onset of type 1 diabetes in the celiac group 
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versus the non-celiac group. Also, there was no difference in the mean duration of diabetes in the 
patients with celiac disease versus those who did not have celiac disease.  8  
 Aktay et al. conducted a prospective cohort study between December 1996 and December 1998 
to determine the prevalence and clinical presentation of celiac disease in children and adolescents with 
juvenile diabetes in Wisconsin, USA, using the serum immunoglobulin A endomysial antibody (IgA-
EMA) as a screening test. In this study 218 patients with diabetes and 117 age and gender matched 
control patients were tested for IgA-EMA. Patients who were positive for IgA-EMA were offered a 
small bowel biopsy.  Histopathologic examination was performed by a pediatric pathologist who made 
the diagnosis of celiac disease based on the following criteria, villous atrophy, inflammation in the 
lamina propria with increased intraepithelial lymphocytes (IEL) and hyperplasia of the crypts. Biopsy 
specimens were classified as having partial or total villous atrophy. Seventeen of the 218 diabetic 
patients (7.7%) had positive IgA-EMA. All control patients were negative for IgA-EMA. Small bowel 
biopsies were performed in 14 diabetic patients. Ten of the patients had villous atrophy and were 
newly diagnosed with celiac disease. The prevalence of CD in DM 1 patients in this study was 4.6% 
(10/ 218). Of the ten newly diagnosed patients with CD, one patient who had mild villous architectural 
alterations and increased intraepithelial lymphocytes had total villous atrophy on a second biopsy.  
Two patients, who were not diagnosed with celiac disease, had minor histological changes such as 
increased intraepithelial lymphocytes, focal acute inflammation, and mild architectural change of villi 
without villi atrophy.  The other two patients had normal mucosal morphologic features. One patient 
who had negative villi atrophy had a repeat biopsy two years later, which showed villous atrophy. This 
increased the initial prevalence of CD in type 1 diabetics from 4.6% to 5.0%. 9 
  Barera et al. conducted a six year prospective longitudinal study, to investigate the prevalence 
of celiac disease in a large cohort of children and adolescents at the onset of type 1 diabetes, and the 
occurrence of new cases during a six year follow up. From January 1993 to January 1999, 274 patients 
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with new onset type 1 diabetes were recruited from Northern Italy. One patient had a diagnosis of 
celiac disease before the onset of type 1 diabetes and was excluded from the study. All patients were 
tested for serum IgA and, if patients were IgA deficient, then they were tested for IgG-antiendomysium 
and IgG-antigliadin antibodies. All 273 eligible patients were tested for IgA-EMA at the onset of type 
1 diabetes and annually up to 6 years. Patients with positive results or two consecutive weak positive 
results were considered appropriate for jejunal biopsy. A pathologist, who was blinded to IgA- EMA 
results, examined the biopsy specimens according to the mucosal change described by the Marsh 
classification. The infiltrative (type 1) lesion comprises normal mucosa architecture in which the 
villous epithelium is markedly infiltrated by small non-mitotic intraepithelial lymphocytes (IEL). The 
hyperplastic (type 2) lesion is similar to the type 1 lesion but with the addition of enlarged crypts the 
epithelium of which, like the villi, is also infiltrated by intraepithelial lymphocytes. The destructive 
(type 3) lesion is characterized by some degree of villous atrophy, with inflammation and hyperplastic 
crypts, and is the classic lesion associated with celiac disease. The diagnosis of CD was considered the 
histological demonstration of the hyperplastic or destructive mucosal lesions , type 2 or 3.  Of the 273 
patients, two were IgA deficient and IgG-antiendomysium and IgG-antigliadin antibody assays tested 
normal in both. Fifteen individuals (5.5%) tested positive with the IgA-EMA assay. Nine presented 
IgA- EMA assay positive and six were only weakly positive. Five of the six patients with weak IgA-
EMA reactivity were negative at the second assay and the intestinal biopsy was not performed. A total 
of ten intestinal biopsies were performed. Nine individuals had hyperplastic or destructive lesions 
consistent with celiac disease. The overall prevalence of CD in these 274 patients with new onset type 
1 diabetes was 3.6%, of which one case was already known and nine were detected by screening. 
Within a four year follow up 12 more patients with a negative IgA-EMA antibody test at diabetes onset 
tested positive. Ten biopsies were performed and seven patients were found to have celiac disease. The 
cumulative prevalence of patients with at least 1 positive IgA-EMA test was 9.9% (27/ 273) and 
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cumulative prevalence of  the entire cohort of patient patients with biopsy proven celiac disease was 
6.2% (10 out of 274). The age of type 1 diabetes onset was not different between patients who had 
celiac disease and those who did not. Therefore, the study determined the age at onset of type 1 
diabetes was not a predictor of celiac disease development. Within 6 years, the risk of developing at 
least one positive IgA-EMA assay was 13.8% and a biopsy confirmed celiac disease was 8.3%. The 
prevalence of CD in type 1 diabetics increased initially from 3.6% to 8.3% in six years. 10  
 Crone et al. conducted a prospective cohort study to test the hypothesis that immunoglobulin A 
anti-endomysial antibody (IgA-EMA) positivity can occur at any time during the course of diabetes. 
All patients from the diabetic mellitus outpatient clinic between 1993 and 2001 at the University 
Children’s Hospital of Vienna were screened for celiac disease with IgA-EMA.  Total IgA levels were 
measured in all patients. In one patient with IgA deficiency, screening with IgG-EMA was performed. 
All patients with positive IgA-EMA underwent small bowel biopsy, and the specimens were analyzed 
according to the Marsh criteria. Follow up data for at least three years, with least two IgA-EMA 
measurements, were available for the 157 diabetic patients. For 37 of 157 patients, the first IgA- EMA 
measurement was performed on manifestation of DM 1. In the rest of the patients the first IgA- EMA 
measurement was taking during the course of DM 1. In 16 of 157 screened patients with diabetes, IgA-
EMA was positive. In group one, 8 out of 37 patients were positive for IgA-EMA (21.6%) and.six of 
them had manifestations of diabetes. Biopsy results of one patient showed normal mucosa, in another 
patient increased intraepithelial lymphocyte counts, indicating a potential for CD, were seen and in 
four other patients, partial to total villous atrophy, celiac disease, was observed. The prevalence of 
celiac disease at this initial testing was 10.8% (4/37). Eleven to 12 months after first screening, two 
additional patients tested positive for IgA-EMA. One patient had a normal mucosa biopsy and the 
other had total villous atrophy (celiac disease). The prevalence increased from 10.8% to 13.5% (5/37). 
In group two, 8 out of 120 patients tested positive for IgA-EMA (6.7%). Biopsy results showed normal 
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mucosa in four patients and partial to villous atrophy, celiac disease, in four other patients. The 
prevalence of biopsy proven celiac disease was 3.3% (4 out 120). 11   
 In 2002, Mankai et al. conducted a prospective cohort study to evaluate the frequency of celiac 
disease among Tunisian children with diabetes mellitus 1. The study was conducted on 205 children 
with DM 1 from four hospitals at the center of Tunisia. All patients were screened for celiac disease by 
determination of immunoglobulin IgA anti-endomysial antibodies (IgA-EMA). IgA-EMA was positive 
in 17 out of 205 children with DM 1 (8.3%).  In 13 out of 17 IgA-EMA positive patients, duodenal 
biopsies were performed (the parents of the 4 remaining IgA- EMA positive children refused biopsy).  
The biopsy specimens were read by two pathologists, who were blinded to patient identity and the 
intestinal mucosa was classified according to the Marsh criteria. 11 out the 13 patients were found to 
have confirmed celiac disease.  Eight patients showed a total villous atrophy and three patients showed 
partial villous atrophy. All 11 patients had elevated counts of intraepithelial lymphocytes. The other 
two patients showed a normal histological picture with a normal number of intraepithelial 
lymphocytes. Only three of the 11 patients had celiac signs or symptoms. Prevalence of celiac disease 
in type 1 diabetics in this study was 5.4% (11/205). 12 
 Salardi et al. conducted a longitudinal study to verify whether the prevalence of the association 
between type 1 diabetes and celiac disease has changed in the last 18 years and whether the 
immunological onset of celiac disease differs among children with type 1 diabetes. In 1987, a 
prospective evaluation of celiac disease related antibodies, in 331 DM 1 pediatric patients was started.  
180 children were diagnosed with DM1 between 1987-1994 and 151 children were diagnosed with 
DM1 between 1995-2004. All of the patients underwent immunological evaluation when diabetes was 
diagnosed and every six to twelve months thereafter, for 18 years. All patients were tested for 
immunoglobulin A anti-endomysial antibodies (IgA-EMA) prospectively from 1994 to 2004, and 
retrospectively, from 1987 to 1993. Before 1994, sensitivity was 95% and specificity was 98%. After 
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1994, sensitivity was 98% and specificity was 100%. The diagnosis of celiac disease was confirmed by 
an intestinal biopsy with a gastroduodenoscopy and multiple biopsies. Histological abnormalities were 
graded according to the Marsh classification. Of the 331 diabetic children enrolled in the study, two 
were affected by celiac disease before being diagnosed with diabetes whereas 29 (8.8%) were found to 
be positive on the IgA-EMA assay upon the diagnosis of diabetes or thereafter. 23 patients underwent 
biopsy (six did not undergo biopsy because two had borderline IgA-EMA positivity and four became 
negative with IgA- EMA retesting). 18 out of 23 had typical lesions and the rest of the patients had 
normal mucosa. The initial prevalence of celiac disease in type 1 diabetic children in this study was 
6.02%, 20 patients, 2 already known and 18 discovered at screening, out of 331. In two of the five 
patients who were initially negative a second biopsy was carried out at 1 and 4.5 years respectively, 
following the onset of clinical symptoms,  and showed typical celiac lesions whereas the three other 
patients were negative for IgA- EMA during post-biopsy follow up of two to eight years did not. 
Therefore, there were 3 false positives (13%) and a total of 22 cases, 20 at initial biopsy and 2 more at 
follow up, of proven biopsy celiac disease.  In this study the overall prevalence of celiac disease in 
type 1 diabetic children increased initially from 6.02% to 6.6%. However, the 22 cases of celiac 
disease were not distributed evenly throughout the observation period rather, the study noted a sudden 
dramatic increase in celiac disease in 1995. The observation period was divided into two parts, before 
1994 and after 1994 and the prevalence of celiac disease was calculated separately in two parts. 
Between 1987 and 1994, among the 180 children with newly diagnosed diabetes, six were affected 
with celiac disease, making the prevalence rate of CD before 1994 3.3% (6/180). Between 1995 and 
2004, 151 new cases of diabetes were diagnosed and 16 were affected with celiac disease, making the 
prevalence rate of CD after 1994 10.6% (16/ 151)13.  
 In 2004, Baptista et al. conducted a prospective cohort study to determine the prevalence of 
celiac disease in Brazilian children and adolescents with type 1 diabetes. 104 pediatric patients with 
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DM 1 and 105 healthy pediatric patients, who were used as a control group, were tested for the 
presence of IgA anti-endomysial antibody (IgA-EMA). Total serum IgA levels were measured to 
detect possible serum IgA deficiency in all patients. In patients with IgA deficiency, IgG-EMA was 
tested. Small bowel biopsies were offered in patients who were IgA-EMA positive. Biopsies were 
analyzed according to a modified Marsh classification. Celiac disease diagnosis was made by the 
following criteria: villous atrophy, elevated intraepithelial lymphocytes (IEL) count, and hyperplasia of 
the crypts.  Among the 104 patients with DM 1, nine patients were positive for IgA-EMA (8.7%). 
Three diabetic patients were IgA deficient but since they were negative for IgG-EMA, they were not 
excluded from the study. All of the healthy controls were negative for IgG-EMA. Two of the nine IgA-
EMA patients had an increased IEL count with subtotal and partial villous atrophy respectively. Three 
other patients had partial villous atrophy with non-elevated IEL counts but were considered as having 
celiac disease. The remaining four patients had normal histology. In this study, the overall results show 
a prevalence of celiac disease of 4.8% (5/104)6.  
Discussion  
 In this systemic review, only prospective studies were found. No randomization studies were 
conducted because celiac disease could not be randomly assigned to patients. The studies utilized a 
select group of individuals with type 1 diabetes rather than the entire population of diabetics and the 
subjects were not randomly selected, therefore only an estimated prevalence of celiac disease could be 
reported. The studies each addressed a large sample of diabetic patients (at least 100 patients per study) 
and showed a prevalence of celiac disease in the DM 1 population to be greater than 3%.  
 In all of the studies, all patients with a positive IgA-EMA were offered biopsies.  All of the 
studies described similar methods used to screen for IgA-EMA and biopsies for celiac disease, so there 
was no difference between the studies in these areas. The biopsies were performed after the IgA-EMA 
results were obtained so the biopsy results were not affected by the IgA-EMA. In fact, three out of the 
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seven articles mentioned that the histopathologists were blinded to the results of the IgA-EMA, which 
also supports the idea that biopsy results were not affected by the IgA-EMA. All of the articles used 
the Marsh criteria in some form, in the diagnosis of celiac disease; therefore there were no differences 
in diagnosing celiac disease on biopsy. However, some patients refused biopsies after testing positive 
for IgA-EMA. The studies conducted by Aktay et al. and Mankai et al. had patients who refused 
biopsies, resulting in it being impossible to reach a definitive conclusion as to whether or not these 
patients had celiac disease.   
 All of the studies tested IgA-EMA on patients with diabetes type 1 and some studies included a 
control group. In the study conducted by Fraser-Reynolds et al. a control group of non-diabetic 
gastrointestinal patients was used, which showed a prevalence of celiac disease to be 8.9% compared 
to the diabetic 1 population which was 5.1%.  This higher prevalence of celiac disease may be due to 
the fact that a smaller specific population, experiencing gastrointestinal symptoms was being tested. 
This was a good comparison because it showed that, although there was an increased prevalence of 
celiac disease in the population with DM 1 it is not as great as the population, which is non-diabetic 
but is experiencing gastrointestinal complaints. Aktay et al. tested IgA-EMA on gender matched 
control patients and all control patients tested negative. This comparison makes a strong point that 
having DM 1 increases the prevalence of positive IgA-EMA. The study conducted by Baptista et al. 
also used a control group, which tested negative for IgA-EMA, therefore emphasizing the point that 
having DM 1 increases an individual’s chance of developing a positive IgA-EMA.  
 Compared to the general population, IgA deficiency is more common in patients with celiac 
disease and can lead to false negative results in the IgA-EMA. The studies conducted by Aktay et al., 
Mankai et al., and Salardi et al. did not test for IgA deficiency so the results of the IgA-EMA in these 
studies could be falsely negative and the actual prevalence of positive IgA-EMA could be higher than 
was stated.  
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 The studies that performed follow up with retesting of IgA-EMA seem to show that it is 
possible for an individual with a negative IgA-EMA to sero-convert to a positive IgA-EMA. The same 
is true of the biopsy; an individual who was initially negative for celiac disease may later develop 
celiac disease and demonstrate a positive biopsy at follow up. This was demonstrated in the study 
conducted by Fraser-Reynolds et al.; one of the IgA-EMA positive patients with an initial normal 
biopsy underwent a second biopsy six months later, which confirmed celiac disease, increasing the 
prevalence of celiac disease from 5.1% to 5.5%. Aktay et al. demonstrated this idea as well in their 
study when one of the patients, who initially had a negative biopsy, had a repeated biopsy two years 
later, which indicated villous atrophy, increasing the prevalence of celiac disease from 4.6% to 5.0%. 
In the study conducted by Barera et al. the prevalence of celiac disease in these diabetic individuals 
was 3.6%. Within four years of follow up, the estimated prevalence of CD increased to 6.2%, and after 
six years the prevalence of CD increased even higher to 8.3%. This study indicated that patients who 
had initially been IgA-EMA negative could become IgA-EMA positive a few years later. This study 
demonstrates that being negative IgA-EMA initially does not prevent an individual from developing 
positive IgA-EMA later on, and that it is possible for an individual who is IgA-EMA negative to 
develop celiac disease. In the study by Crone et al. the initial prevalence of celiac disease at the onset 
of diabetes was 10.8%.  One year later, a patient who initially tested negative for IgA-EMA became 
positive and the biopsy demonstrated celiac disease; increasing the prevalence of celiac disease to 
13.5%. This increase in prevalence rate showed that seroconversion occurred and a negative IgA-EMA 
does not rule out the development of celiac disease later on. The study conducted by Salardi et al. 
showed an initial prevalence of celiac disease to be 6.2% but at follow up two patients, who were 
initially negative at biopsy had a second biopsy, which showed celiac disease to be present and 
increased the prevalence to 6.6%. This also supports the idea the seroconversion can occur in those 
who initially had a negative biopsy.  
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 These studies that performed follow up did not follow everyone who was negative IgA-EMA to 
see if they developed positive IgA-EMA later on, therefore the estimated prevalence rate of positive 
IgA-EMA could actually be higher than was stated if follow up was performed.  This is true of the 
biopsy as well; not all patients who had a negative biopsy initially received a follow up biopsy so 
prevalence of celiac disease could also be underestimated.  
 Some of the studies stated that age at onset and duration of diabetes does not affect the 
prevalence rate of celiac disease but this may not be the case. In fact, the study conducted by Barera et 
al. mentioned that incidence of celiac disease increased with the duration of diabetes because patients 
were screened at several times rather than just at one point. Also the study conducted by Mankai et al. 
stated that DM 1 patients with positive IgA-EMA had earlier onset of DM 1 compared to those who 
were negative for IgA-EMA. The studies that performed follow up on patients demonstrated that those 
who were initially negative at screening with IgA-EMA later seroconverted to positive IgA-EMA and 
developed latent celiac disease. Patients who developed latent celiac disease had a longer duration of 
diabetes, which could in fact be the cause of seroconversion but this issue was not addressed and 
should be in future studies.   
 Since there seems to be a link between diabetes and celiac disease along with the possibility of 
seroconversion all the studies recommended that initial screening for celiac disease is necessary for 
those with DM1 and state the importance of follow up screening.  However, the studies conducted by 
Barera et al., Crone et al., and Mankai et al. were the only studies that mentioned at what interval 
screening should be performed after diabetes diagnosis. The term “several years” is vague and does not 
give a definitive answer as to exactly how often testing should be performed. The recommendation of 
annual screening helps determine at what interval screening should be performed but also does not 
address for how many years. The range of two to five years is wide and variable, which does not give a 
definite screening schedule.  The questions that still need to be addressed are “at what intervals and for 
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how long should DM 1 patients be screened and biopsed for celiac disease?”  The studies also do not 
mention the cost of the screening or the biopsies so affordability of the tests is undetermined. If the 
testing for IgA-EMA and biopsies are costly, frequent testing and follow up may not be possible due to 
the high cost.   
Conclusion 
 There seems to be a link between celiac disease and diabetes type 1. Having DM 1 increases an 
individual’s chance of a positive IgA-EMA result and his risk of developing celiac disease.  Compared 
to the population who is experiencing gastrointestinal symptoms and having problems with 
malabsorption, the risk of CD in the DM 1 patient is not as great, but compared to the general 
population without any symptoms, the risk is greater. Therefore, it is important to screen for celiac 
disease in the DM 1 patient especially if they are experiencing gastrointestinal symptoms.  Due to this 
link and the possibility of seroconversion, initial screening of celiac disease in the DM 1 population 
and follow up with retesting, is recommended.  Testing patients for celiac disease at more than one 
point in their disease may help better answer the question as to whether or not having diabetes longer 
increases the individual’s risk of developing celiac disease. It is also important to test all patients for 
IgA deficiency to make the IgA-EMA results more valid. Without testing for this deficiency, the IgA-
EMA results could be falsely negative, therefore underestimating the prevalence of positive IgA-EMA 
results. If an individual is IgA deficient and is not tested, then a biopsy is not performed because it is 
thought that they are IgA-EMA negative, and a possible celiac disease diagnosis can be missed.  
Detecting celiac disease early is important in the treatment of the disease. By catching the disease 
earlier in its course, morbidity issues such as vitamin deficiencies, poor glucose control and growth 
failure could be prevented.  
 The studies show that the initial screening for celiac disease in DM 1 patients is important but 
the question at what interval and for how long follow up should be performed still needs to be 
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addressed. The cost of the biopsy and whether or not insurance will pay for follow up testing needs to 
be looked into because frequent testing may not be available to patients if the tests are not affordable.  
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Table 1. Research Matrix of Journal Articles that Pertained to the Clinical Question 
Author /Journal Title Year 
Published 
Patients/  
Population  
Positive IgA-EMA  Positive Biopsy  Study Type 
Fraser-Reynolds, K.A. et al./Use of IgA-EMA to 
screen for celiac disease in North American children 
with type 1 diabetes 
1998   236 DM 1 patients  
  56 GI patients 
 19 DM 1 patients (8%) 
 3 GI patients (5.4%) 
 12 DM I patients 
(5.1%) 
 5 GI patients (8.9%)  
Prospective Cohort 
Aktay, A.N. et al. / The Prevalence and Clinical 
Characteristics of Celiac Disease in Juvenile 
Diabetes in Wisconsin / Journal of Pediatric 
Gastroenterology and Nutrition 
2001 218 DM 1 patients 
117 control patients 
17 DM 1 patients 
(7.7%) 
All controls were 
negative 
10 DM 1 patients 
(4.6%) initially  
11 DM 1 patients 
(5.0%) at follow up  
Prospective  
Cohort 
Barera, G. et al./ Occurrence of Celiac Disease after 
onset of Type 1 Diabetes: a 6- year prospective 
longitudinal study / Pediatrics 
2002 274 DM 1 patients 15 DM 1 patients  
(5.5%) initially  
In 4 yrs- 9.9%  
In 6 yrs- 13.8% 
10 DM 1 patients 
(3.6%) initially  
In 4 yrs –6.2%  
In 6 yrs- 8.3%  
Prospective 
longitudinal  
Crone, J. et al / Prevalence of Celiac Disease and 
Follow up of EMA in children and adolescents with 
Type I diabetes/ Journal of Pediatric 
Gastroenterology and Nutrition 
2003 157 DM 1 patients 
(37 were at the onset of 
diabetes and 120 were 
during the course of 
diabetes)  
8 DM 1 patients at 
onset of diabetes  
(21.6%)  
8 DM 1 patients in the 
course of diabetes 
(6.7%)  
Onset: 4 DM 1 patients 
(10.8%) initially.  5 
DM 1 (13.5%) patients 
at follow up  
Duration: 4 DM 1 
patients (3.3%)  
Prospective cohort   
Mankai, A. et al/Screening by anti-endomysium 
antibodies for celiac disease in Tunisian children 
with type 1 diabetes mellitus/Gastroenterology 
Clinic and Biology 
2007 205 DM 1 patients 17 DM 1 patients 
(8.3%)  
11 DM 1 patients 
(5.4%)  
Prospective Cohort 
Salardi, S. et al/ Prevalence of Celiac Disease with 
Type I DM Increased in the Mid-1990s: An 18 year 
Longitudinal Study Based on Anti-endomysial 
antibodies/Journal of Pediatric Gastroenterology 
and Nutrition   
2008 331 DM 1 patients 
(180 diagnosed before 
1994 and 151 
diagnosed after 1994)  
29 DM 1 patients 
(8.8%)  
20 DM 1 patients 
(6.02%)  initially  
22 DM 1 patients 
(6.6%) at follow up   
6 DM 1 patients (3.3%) 
before 1994 and 16 DM 
1 patients (10.6% after 
1994)  
Prospective & 
Retrospective 
Longitudinal 
Baptista, M.L. et al./Prevalence of Celiac Disease in 
Brazilian Children and Adolescents with Type 1 
Diabetes Mellitus/Journal of Pediatric 
Gastroenterology and Nutrition 
2005 104 DM 1 patients  
105 control patients 
9 DM 1 patients (8.7%)  
All controls were 
negative  
5 DM 1 patients (4.8%)  Prospective Cohort 
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Table II. Validity of Research Articles that Pertained to Clinical Questions 
 
Author/  Title/ Journal Was there an independent  
blind comparison with a 
reference standard?  
Was the diagnostic test 
evaluated in an 
appropriate spectrum of 
patients (like those in 
whom it may be used in 
practice?)  
Was the reference 
standard applied 
regardless of the 
diagnostic test 
result?  
Were the methods of the 
test described in 
sufficient detail to permit 
replication? 
Validity 
Score 
Fraser-Reynolds, K.A. et al./Use 
of IgA-EMA to screen for celiac 
disease in North American 
children with type 1 diabetes 
Yes. The reference standard, the 
biopsy was performed on those 
who were positive for  IgA-EMA. 
The IgA-EMA results were not 
affected by the biopsy results 
because the IgA-EMA was 
performed prior to the biopsy. 
Pathologist was unaware of pt’s 
information.   
Yes. The diagnostic test, IgA-
EMA was performed on all 
patients with DM I along with 
comparison group of GI pts. The 
IgA-EMA was used to determine 
if those who have DM I were at 
a greater risk of developing CD 
compared to those who did not 
have DM I but had GI 
complaints.  
Cannot tell because in 
biopsies were performed 
in only DM I pts with 
positive IgA-EMA. But in 
the GI pts with negative 
IgA-EMA biopsies were 
performed.  
Yes. The IgA-EMA, biopsy, 
histology and statistical analysis 
were discussed in detail.  
3 
Aktay, A.N. et al. / The 
Prevalence and Clinical 
Characteristics of Celiac Disease 
in Juvenile Diabetes in 
Wisconsin / Journal of Pediatric 
Gastroenterology and Nutrition  
Yes. The reference standard was 
the biopsy, which were offered for 
those who had a positive IgA-
EMA. The results of the IgA-EMA 
were not affected by the biopsy 
because the IgA-EMA was 
performed beforehand.  
Yes. The diagnostic test, IgA-
EMA was performed on all 
patients with DM I and the 
match control patients. The IgA-
EMA was used to determine if 
DM I pts are a greater risk for 
CD compared to the control pts.  
No. The biopsy was not 
performed unless the IgA-
EMA was positive and for 
3 of the positive pts. 
refused the biopsy.  
Yes. The IgA-EMA, biopsy and 
pathology was discussed in 
detail.  
3 
Barera, G. et al./ Occurrence of 
Celiac Disease after onset of 
Type 1 Diabetes: a 6- year 
prospective longitudinal study / 
Pediatrics 
Yes. The reference standard was 
the biopsy which was performed 
with a positive IgA-EMA. The 
results of the IgA-EMA were not 
affected by the biopsy because the 
IgA-EMA was performed before 
the biopsy. Pathologist was blinded 
to IgA-EMA results.  
Yes. The diagnostic test IgA-
EMA was used to determine if 
those who have DM I are at risk 
for developing CD.  Follow up 
studies were also done to 
determine if duration of DM I 
increases the risk of CD.  
No.  The biopsy was 
performed only in those 
who had a positive IgA-
EMA.  
Yes. This article went into great 
detail of how the IgA-EMA and 
biopsies along with the histology 
were performed.  
3 
Crone, J. et al / Prevalence of 
Celiac Disease and Follow up of 
EMA in children and adolescents 
with Type I diabetes/ Journal of 
Pediatric Gastroenterology and 
Nutrition  
Yes. The reference standard was 
the biopsy which was performed 
with a positive IgA-EMA. The 
results of the IgA-EMA did not 
affect the results of the biopsy 
because the IgA-EMA was 
performed beforehand.  
Yes. The diagnostic test IgA-
EMA was used to determine if 
having DMI puts an individual at 
risk for developing CD. Follow 
up studies were also done to 
determine if prevalence of CD 
was greater during the course of 
DMI than the onset.  
No. The biopsy was 
performed only in those 
who had a positive IgA-
EMA.  
Yes. The article discussed how 
the IgA-EMA and biopsy were 
performed in detail. Histology of 
the biopsy was discussed as 
well.  
3 
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Mankai, A. et al/Screening by 
anti-endomysium antibodies for 
celiac disease in Tunisian 
children with type 1 diabetes 
mellitus/Gastroenterology Clinic 
and Biology 
Yes. The reference standard, the 
biopsy was performed for pts who 
had a positive IgA-EMA. The 
results of the IgA-EMA were not 
affected by the biopsy results 
because the IgA-EMA was 
performed first. The pathologists 
were blinded of the IgA-EMA 
results as well.  
Yes. The IgA- EMA was 
performed on all patients with 
DM I to determine if having DM 
increases an individual’s risk of 
developing CD.  
No. The biopsy was not 
performed unless the pt. 
had a positive IgA-EMA. 
4 of the positive IgA-
EMA pts refused biopsies.  
Yes. The IgA-EMA, biopsy, 
histology and statistical analysis 
were explained detail.  
3 
 Salardi, S. et al/ Prevalence of 
Celiac Disease with Type I DM 
Increased in the Mid-1990s: An 
18 year Longitudinal Study 
Based on Anti-endomysial 
antibodies/Journal of Pediatric 
Gastroenterology and Nutrition   
Yes. The reference standard, 
biopsy was performed on those 
were positive for  IgA-EMA. The 
IgA-EMA results were not affected 
by the biopsy results because the 
IgA-EMA was performed 
beforehand. Reproducibility of the 
test (performed in double blind) 
was high.  
Yes. The diagnostic test was 
performed on all patients with 
DM I. Follow up study was 
performed to determine if longer 
onset of DM I increases risk of 
developing CD.  
 
 
 
 
No. Biopsies were 
performed with only 
positive IgA-EMA and 2 
of the positive pts. refused 
the biopsies.  
Yes. The IgA-EMA, biopsy and 
histology methods along with 
the statistical analysis were 
discussed in detail.  
3 
Baptista, M.L. et al./Prevalence 
of Celiac Disease in Brazilian 
Children and Adolescents with 
Type 1 Diabetes 
Mellitus/Journal of Pediatric 
Gastroenterology and Nutrition  
Yes. The reference standard, the 
biopsy was performed for pts., who 
had positive IgA-EMA. The results 
of the IgA-EMA were not affected 
by the biopsy because the IgA-
EMA was performed first.   
Yes. The IgA-EMA was 
performed in all pts to determine 
if DM I pts. have a greater risk 
of developing CD compared to 
the controls.  
No. The biopsy was 
performed only on those 
with positive IgA-EMA 
results.  
Yes. The IgA-EMA, biopsy, and 
statistical analysis methods were 
discussed in detail.  
3 
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